SG85628A1 - Compound and its use - Google Patents

Compound and its use

Info

Publication number
SG85628A1
SG85628A1 SG9901252A SG1999001252A SG85628A1 SG 85628 A1 SG85628 A1 SG 85628A1 SG 9901252 A SG9901252 A SG 9901252A SG 1999001252 A SG1999001252 A SG 1999001252A SG 85628 A1 SG85628 A1 SG 85628A1
Authority
SG
Singapore
Prior art keywords
compound
Prior art date
Application number
SG9901252A
Other languages
English (en)
Inventor
Lorraine Mary Edmeades
Nigel Arthur Griffith-Skinner
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10833464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG85628(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SG85628A1 publication Critical patent/SG85628A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
SG9901252A 1998-06-10 1999-02-25 Compound and its use SG85628A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812413.4A GB9812413D0 (en) 1998-06-10 1998-06-10 Compound and its use

Publications (1)

Publication Number Publication Date
SG85628A1 true SG85628A1 (en) 2002-01-15

Family

ID=10833464

Family Applications (1)

Application Number Title Priority Date Filing Date
SG9901252A SG85628A1 (en) 1998-06-10 1999-02-25 Compound and its use

Country Status (31)

Country Link
US (1) US6333198B1 (sh)
EP (2) EP1170588A1 (sh)
JP (1) JP2989189B1 (sh)
KR (1) KR100322354B1 (sh)
CN (2) CN1238454A (sh)
AP (3) AP9901481A0 (sh)
AR (1) AR014074A1 (sh)
AT (1) ATE218552T1 (sh)
AU (1) AU2031999A (sh)
BR (1) BR9900984A (sh)
CA (1) CA2265194C (sh)
DE (1) DE69901656T2 (sh)
DK (1) DK0963980T3 (sh)
EA (1) EA000666B1 (sh)
ES (1) ES2178342T3 (sh)
GB (1) GB9812413D0 (sh)
HR (1) HRP990074A2 (sh)
HU (1) HUP9900592A3 (sh)
ID (1) ID22957A (sh)
MA (1) MA24777A1 (sh)
NO (2) NO991151L (sh)
NZ (1) NZ334590A (sh)
PE (1) PE20000332A1 (sh)
PL (1) PL331870A1 (sh)
PT (1) PT963980E (sh)
SG (1) SG85628A1 (sh)
SI (1) SI0963980T1 (sh)
TR (1) TR199900520A3 (sh)
UY (1) UY25946A1 (sh)
YU (1) YU12399A (sh)
ZA (1) ZA991951B (sh)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
WO2001049669A1 (en) * 2000-01-03 2001-07-12 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
MXPA03005882A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado amida de amlodipina.
GB2371862B (en) 2000-12-29 2004-07-14 Bioorg Bv Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
CA2433181C (en) 2000-12-29 2005-11-22 Pfizer Limited Amlodipine hemifumarate
IL156692A0 (en) 2000-12-29 2004-01-04 Pfizer Ltd Process for making amlodipine maleate
AT5874U1 (de) 2000-12-29 2003-01-27 Bioorg Bv Pharmazeutische zubereitungen enthaltend amlodipinmaleat
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
MXPA03005886A (es) 2000-12-29 2005-04-19 Pfizer Ltd Derivado de aspartato de amlodipina como antagonista del canal de calcio.
EP1309554A1 (en) 2000-12-29 2003-05-14 Synthon Licensing, Ltd. Amide derivative of amlodipine
DE60116514T2 (de) 2000-12-29 2006-08-17 Pfizer Ltd., Sandwich Amlodipinhemimaleat
DE10134980C2 (de) 2001-07-17 2003-05-28 Helm Ag Verfahren zur Herstellung von Lamotrigin
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
US20030216376A1 (en) * 2002-03-20 2003-11-20 Revital Lifshitz-Liron Crystalline forms of quetiapine hemifumarate
HU225667B1 (en) * 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
EP1562912A2 (en) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
ATE507209T1 (de) * 2003-12-02 2011-05-15 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
CA2554789A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries, Ltd. Montelukast sodium polymorphs
CA2554572A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
MD2823G2 (ro) * 2004-02-12 2006-05-31 Институт Химии Академии Наук Молдовы Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
DE602005015174D1 (de) * 2004-04-21 2009-08-13 Teva Pharma Verfahren zur herstellung von montelukast-natrium
EP1740564A2 (en) * 2004-04-26 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105771A1 (en) 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US7439398B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals S.R.L. Enantiomerically pure atomoxetine and tomoxetine mandelate
CA2573857A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
DE602005020014D1 (de) * 2004-07-20 2010-04-29 Teva Gyogyszergyar Zartkoeruen Kristallines mycophenolat-natrium
US7473804B2 (en) 2004-07-22 2009-01-06 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
EP1692134A2 (en) * 2004-09-04 2006-08-23 Teva Pharmaceutical Industries, Inc. A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
US20060081361A1 (en) * 2004-09-13 2006-04-20 Gabbey Lawrence W Oil cooler with integral filter
TW200825092A (en) * 2004-09-28 2008-06-16 Teva Pharma A method for reducing the level of AED in atorvastatin calcium sample
JP2007514777A (ja) * 2004-10-19 2007-06-07 テバ ファーマシューティカル インダストリーズ リミティド テガセロッドマレエートの精製
US7678551B2 (en) * 2004-10-25 2010-03-16 Seradyn, Inc. Immunoassays for lamotrigine
EP1730132A2 (en) * 2004-12-23 2006-12-13 Teva Pharmaceutical Industries Ltd Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
MX2007007302A (es) * 2005-01-11 2008-02-11 Teva Pharm Fine Chemicals Srl Proceso para la preparacion de clorhidrato de 1-amino-3,5-dimetiladamantano.
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
EP1851206B1 (en) * 2005-02-22 2012-08-15 Teva Pharmaceutical Industries, Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
CA2602073A1 (en) * 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
TW200639162A (en) * 2005-03-14 2006-11-16 Teva Pharma Pure duloxetine hydrochloride
EP1751085A1 (en) * 2005-04-05 2007-02-14 Teva Pharmaceutical Fine Chemicals S.R.L. Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
EP1866275A1 (en) * 2005-04-06 2007-12-19 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
CN101300224A (zh) * 2005-04-11 2008-11-05 特瓦制药工业有限公司 制备(s)-普瑞巴林的方法
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
EP1869007A1 (en) * 2005-04-14 2007-12-26 Teva Pharmaceutical Industries Ltd Process for preparing quetiapine fumarate
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP1879852A1 (en) * 2005-05-10 2008-01-23 Teva Pharmaceutical Industries Ltd Pregabalin free of lactam and a process for preparation thereof
ATE523484T1 (de) * 2005-05-10 2011-09-15 Teva Pharma Optische lösung a us 3-carbamoylmethyl-5-methyl- hexansäure
WO2006122258A1 (en) * 2005-05-10 2006-11-16 Teva Pharmaceutical Industries Ltd. Method for the preparation of pregabalin and salts thereof
BRPI0605833A (pt) * 2005-05-10 2007-12-18 Teva Pharma pregabalina livre de ácido isobutilglutárico e um processo para sua preparação
KR20070083471A (ko) 2005-05-23 2007-08-24 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 염산염 결정형 ｉ의 제조 방법
EP1896429A2 (en) * 2005-06-27 2008-03-12 Sicor, Inc. A purification process for anastrozole intermediate
WO2007002720A2 (en) * 2005-06-27 2007-01-04 Sicor, Inc. An impurity of anastrozole intermediate, and uses thereof
ES2358923T3 (es) * 2005-07-05 2011-05-16 Teva Pharmaceutical Industries, Ltd. Purificación de montelukast.
JP2008515931A (ja) * 2005-08-16 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 結晶形ロスバスタチン中間体
WO2007035789A1 (en) * 2005-09-19 2007-03-29 Teva Pharmaceutical Industries Ltd. Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin
US20070197529A1 (en) * 2005-12-01 2007-08-23 Viviana Braude Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
WO2007069264A2 (en) * 2005-12-15 2007-06-21 Alembic Limited Reference standards for determining the purity of telithromycin and processes therefor
CA2630478A1 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries, Ltd Processes for preparing darifenacin hydrobromide
ES2310504T1 (es) * 2006-03-27 2009-01-16 Teva Pharmaceutical Fine Chemicals S.R.L. Procedimiento para la preparacion de clorhidrato de memantina sustancialmente libre de impurezas.
US20080146675A1 (en) * 2006-04-05 2008-06-19 Eugenio Castelli Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
GB0609835D0 (en) * 2006-05-18 2006-06-28 Pliva Istrazivanje I Razvoj D Impurities of a pharmaceutical product
US7462738B2 (en) * 2006-05-24 2008-12-09 Teva Pharmaceutical Industries Ltd. Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof
WO2007143113A2 (en) * 2006-05-31 2007-12-13 Teva Pharmaceutical Industries Ltd. The use of enzymatic resolution for the preparation of intermediates of pregabalin
US20080015385A1 (en) * 2006-05-31 2008-01-17 Lilach Hedvati Preparation of (S)-pregabalin-nitrile
US20080009050A1 (en) * 2006-06-29 2008-01-10 Zdenek Pokluda Regulation of acid metabolite production
US20120142919A1 (en) * 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
WO2008019798A1 (en) * 2006-08-14 2008-02-21 Lonza Ag A process for the preparation of lamotrigine
WO2008106179A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
US8097754B2 (en) * 2007-03-22 2012-01-17 Teva Pharmaceutical Industries Ltd. Synthesis of (S)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
TW200904982A (en) * 2007-04-11 2009-02-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Method for reducing impurity level in mycophenolic acid fermentation
EP2069320A2 (en) * 2007-05-31 2009-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2009046309A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Pregabalin -4-eliminate, pregabalin 5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof
KR20100058660A (ko) * 2007-10-23 2010-06-03 테바 파마슈티컬 인더스트리즈 리미티드 다사티닙 다형체 및 이의 제조 방법
US20090281176A1 (en) * 2007-11-01 2009-11-12 Vinod Kumar Kansal Process for the synthesis of ramelteon and its intermediates
US8486927B2 (en) * 2007-11-09 2013-07-16 Thar Pharmaceuticals Crystalline forms of lamotrigine
WO2009151494A1 (en) * 2008-03-06 2009-12-17 Teva Pharmaceutical Industries Ltd. Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities
WO2009158343A1 (en) * 2008-06-23 2009-12-30 Teva Pharmaceutical Industries, Ltd. Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester
US20100152468A1 (en) * 2008-10-16 2010-06-17 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
WO2011121452A2 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
CN102766104A (zh) * 2012-08-20 2012-11-07 三金集团湖南三金制药有限责任公司 一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
CN110467560A (zh) 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
KR102270026B1 (ko) * 2020-01-31 2021-06-28 현대약품 주식회사 (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
CN113156009B (zh) * 2021-04-20 2023-12-22 三金集团湖南三金制药有限责任公司 高效液相色谱分析拉莫三嗪的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020934A1 (en) * 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3062603D1 (en) 1979-06-01 1983-05-11 Wellcome Found 3,5-diamino-1,2,4-triazine derivatives, process for preparing such compounds and pharmaceutical compositions containing them
ZA803250B (en) 1979-06-01 1982-01-27 Wellcome Found Substituded aromatic compounds
GB8613183D0 (en) 1986-05-30 1986-07-02 Wellcome Found Triazine salt
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996020934A1 (en) * 1994-12-30 1996-07-11 The Wellcome Foundation Limited Process for the preparation of lamotrigine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAILSTAD J.M. & FINDLAY J.W.A.: "Immunofluorometric assay for lamotrigine (Lamictal) in human plasma" THERAPEUTIC DRUG MONITORING, US, RAVEN PRESS, NEW YORK, NY, vol. 13, no. 5, September 1991 (1991-09), pages 433-442, XP000882274 *

Also Published As

Publication number Publication date
BR9900984A (pt) 2000-05-02
MA24777A1 (fr) 1999-10-01
PT963980E (pt) 2002-10-31
SI0963980T1 (en) 2002-12-31
JP2989189B1 (ja) 1999-12-13
KR20000005611A (ko) 2000-01-25
NO20032753L (no) 1999-12-13
HRP990074A2 (en) 2000-10-31
PL331870A1 (en) 1999-12-20
GB9812413D0 (en) 1998-08-05
DK0963980T3 (da) 2002-09-16
ID22957A (id) 1999-12-23
HUP9900592A3 (en) 2002-04-29
NO991151L (no) 1999-12-13
AP9901481A0 (en) 1999-03-31
EA000666B1 (ru) 2000-02-28
EA199900159A1 (ru) 1999-12-29
YU12399A (sh) 2002-08-12
JP2000009714A (ja) 2000-01-14
ZA991951B (en) 1999-08-16
EP0963980A3 (en) 2000-05-31
DE69901656T2 (de) 2003-01-30
US6333198B1 (en) 2001-12-25
AP2001002286A0 (en) 2001-12-31
DE69901656D1 (de) 2002-07-11
CN1238454A (zh) 1999-12-15
HU9900592D0 (en) 1999-04-28
NO991151D0 (no) 1999-03-10
NZ334590A (en) 2000-07-28
EP1170588A1 (en) 2002-01-09
TR199900520A2 (en) 2000-01-21
AP0102286A0 (en) 2000-09-10
CN1306210A (zh) 2001-08-01
ES2178342T3 (es) 2002-12-16
PE20000332A1 (es) 2000-04-10
EP0963980A2 (en) 1999-12-15
AR014074A1 (es) 2001-01-31
EP0963980B1 (en) 2002-06-05
NO20032753D0 (no) 2003-06-17
TR199900520A3 (tr) 2000-01-21
ATE218552T1 (de) 2002-06-15
AU2031999A (en) 2000-01-06
UY25946A1 (es) 2000-12-29
CA2265194C (en) 2000-10-10
HUP9900592A2 (hu) 2000-04-28
KR100322354B1 (ko) 2002-02-07

Similar Documents

Publication Publication Date Title
AP2001002286A0 (en) Compound and its use
IL128869A0 (en) Pyrozolopyrimidines and pyrazolotriazines
HU9903361D0 (en) Filter-device with collecting-vessel and with heating-device
EP1102535A4 (en) COMPOUNDS AND METHODS
IL139145A0 (en) New use
GB9813271D0 (en) Composition and use
ZA985096B (en) Composition compound and use
PL347357A1 (en) Novel composition and use
GB9818914D0 (en) Use
GB9814640D0 (en) New use
EP1056455A4 (en) EPIMORPHIN COMPOUND AND USE OF THE SAME
GB9817235D0 (en) Compound,composition and use
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
PL332616A1 (en) Hydoxymethylhexanones as odorising and savourising agents
GB9817236D0 (en) Compound,composition and use
EP1058550A4 (en) SUBSTITUTED SEMICARBAZIDES AND THEIR USE
GB9718876D0 (en) Compound,composition and use
GB9803232D0 (en) Compound composition and use
HUP0104723A3 (en) New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use
GB9817238D0 (en) Compound,composition and use
GB9927927D0 (en) Compound composition and use
GB9807503D0 (en) Use
GB9828004D0 (en) Use
GB9817064D0 (en) New use
GB9817911D0 (en) New use